CRMD vs PFE
CRMD: A commercial-stage biopharmaceutical company focused on preventing catheter-related bloodstream infections and delivering a portfolio of hospital-based anti-infective therapies. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | CRMD | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $7.57 | $30.11 | |
| Market cap | $590M | $171.6B | |
| P/E as of 2026-10-20 | 3.47 | 39.62 | CRMD lower |
| Net margin FY2025, SEC XBRL | +52.3% | +12.4% | CRMD higher |
| Gross margin FY2025, SEC XBRL | +88.5% | n/a | |
| Operating margin FY2025, SEC XBRL | +48.2% | n/a | |
| ROE FY2025, SEC XBRL | +40.2% | +9.0% | CRMD higher |
| ROA FY2025, SEC XBRL | +19.7% | +3.7% | CRMD higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-28 | n/a | 0.74 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +617.0% | -1.6% | CRMD higher |
| Revenue CAGR (3y) SEC XBRL | +535.6% | -14.8% | CRMD higher |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-03 | 0.79 | 0.38 | |
| 1-year return as of 2026-10-20 close | -37.7% | +22.0% | PFE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.